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A B S T R A C T
Lung cancer is the leading cause of cancer-related deaths. Late diagnosis and inadequate therapies contribute to
poor outcomes. MicroRNAs (miRNAs) are small non-coding RNAs and are involved in lung cancer development.
Because miRNAs simultaneously regulate several cancer-related genes, they represent an interesting therapeutic
approach for cancer treatment. We have developed Coated Cationic Lipid-nanoparticles entrapping miR-660
(CCL660) and intraperitoneally administered (1.5mg/Kg) twice a week for four weeks into SCID mice carrying
subcutaneously lung cancer Patients Derived Xenografts (PDXs). Obtained data demonstrated that miR-660 is
down-regulated in lung cancer patients and that its replacement inhibited lung cancer growth by inhibiting the
MDM2-P53 axis. Furthermore, systemic delivery of CCL660 increased miRNA levels in tumors and signiﬁcantly
reduced tumor growth in two diﬀerent P53 wild-type PDXs without oﬀ-target eﬀects. MiR-660 administration
reduced cancer cells proliferation by inhibiting MDM2 and restoring P53 function and its downstream eﬀectors
such as p21. Interestingly, anti-tumoral eﬀects of CCL660 also in P53 mutant PDXs but with a functional p21
pathway were observed. Stable miR-660 expression inhibited the capacity of H460 metastatic lung cancer cells
to form lung nodules when injected intravenously into SCID mice suggesting a potential role of miR-660 in
metastatic dissemination.
To investigate the potential toxic eﬀects of both miRNAs and delivery agents, an in vitro approach revealed
that miR-660 replacement did not induce any changes in both mouse and human normal cells. Interestingly,
lipid-nanoparticle delivery of synthetic miR-660 had no immunological oﬀ-target or acute/chronic toxic eﬀects
on immunocompetent mice. Altogether, our results highlight the potential role of coated cationic lipid-nano-
particles entrapping miR-660 in lung cancer treatment without inducing immune-related toxic eﬀects.
1. Introduction
Lung cancer is a disease with a poor prognosis, accounting for 20%
of total cancer-related deaths in Europe [1]. The majority of lung
cancers are represented by the non-small cell lung cancer (NSCLC)
subtype that has a 5-year survival rate of< 18% [2]. Currently, surgical
resection is the most common treatment for early-stage tumors and is
combined with chemotherapeutic agents for patients with advanced
lung cancer; chemotherapy alone is used for patients with metastatic
disease [3]. Platinum-based treatment is commonly used in clinical
practice, with a small eﬀect on improving the survival of patients with
lung cancer [4]. The discovery of activating mutations in the EGFR gene
(23%) and rearrangements in the anaplastic lymphoma kinase (ALK)
gene (3–7%) [5] had a relevant impact on the treatment of patients
with lung cancer, based on their responsiveness to tyrosine kinase in-
hibitors (TKIs), such as erlotinib, crizotinib and geﬁtinib [6,7]. Re-
cently, pembrolizumab was approved as a ﬁrst-line treatment for pa-
tients with lung cancer expressing high levels of programmed cell death
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ligand 1 (PD-L1) [8]. Unfortunately, targeted therapies and pem-
brolizumab represent the ﬁrst-line treatments for only 30% of patients
[9]. Thus, the identiﬁcation of novel treatment strategies remains a
critical and essential need for lung cancer management.
The tumor suppressor gene P53 plays an important role in pre-
venting cancer development and is mutated/deleted in 50% of NSCLC
cases [10]. P53 activity is ﬁnely controlled and, among P53modulators,
mouse double minute 2 (MDM2) plays an important role [11]. Fur-
thermore, MDM2 function is linked to P53 through an autoregulatory
feedback loop under both normal and pathological conditions [12,13].
Based on these considerations, strategies that restore P53 function by
inhibiting MDM2 represent a potential therapy for P53 wild-type lung
cancers [14].
MicroRNAs (miRNAs) are small non-coding, 22 nucleotides long
RNAs that bind complementary sequences of target mRNAs to induce
their degradation or repress translation [15]. Recent studies have re-
ported altered expression patterns of miRNAs in several human ma-
lignancies, including lung cancer [16]. The revelation that miRNAs
function as potential oncogenes and tumor suppressors has generated
great interest in using them as targets for cancer therapy [17]. We
previously identiﬁed miR-660 as a tumor suppressor miRNA in lung
cancer cells. The replacement of this miRNA inhibits the migration and
invasion of tumor cells and blocks tumor growth both in vitro and in
vivo. The anti-tumor eﬀects are mediated by MDM2 downregulation
and activation of the P53 pathway [18].
The roles of miRNAs as novel therapeutic agents have received in-
creasing attention [19]. Although several pre-clinical studies examining
miRNAs have been conducted over the years, only a few have transi-
tioned into clinical development. Several obstacles must be overcome to
envisage the clinical use of miRNA therapy. These challenges include
the design of optimal miRNA delivery vehicles with higher stability or
reduction of oﬀ-target eﬀects and toxicity [20].
Several delivery methods, such as nanoparticles, viral vectors and
liposomes, are available to restore the expression of tumor suppressor
miRNAs [21]. Due to their size and hydrophobic and hydrophilic
characters (in addition to biocompatibility), liposomes represent a
promising system for miRNA delivery because they protect and deliver
nucleic acids and exhibit reduced toxicity and an improved therapeutic
index [22,23]. Because Coated Cationic Lipid-nanoparticles (CCL) car-
riers have been shown to eﬃciently deliver asODNs/siRNAs/miRNAs
[24–27], in the present study, we generated novel lipidic nanoparticles
entrapping miRNA-660 (CCL660) as a lung cancer treatment to explore
its potential for inhibiting lung cancer cell growth.
Thus, we aimed to i) evaluate the anti-tumor activity of CCL660 in
patient-derived xenograft (PDX) models of lung cancer [28]; ii) eluci-
date the mechanism of action of CCL-delivered miR-660 within tumor
cells; and iii) evaluate the acute and chronic toxicity of this lipid-na-
noparticles formulation in mouse models.
2. Results
2.1. Characterization of Coated Cationic Lipid-nanoparticles (CCL)
entrapping miRNAs
The CCLs were designed according to the number of negative
charges of the miRNA sequence, obtaining a miRNA entrapment eﬃ-
ciency of approximately 85–90%. Lipid-nanoparticles possess a mean
hydrodynamic diameter of 121 ± 6 nm for CCL660 and 123 ± 5 nm
for CCLSCR, with a mean polydispersity index (PdI) of 0.092 ± 0.018
for CCL660 and 0.095 ± 0.019 for CCLSCR, indicating that we ob-
tained a good monodisperse preparation (Table 1). Moreover, the two
formulations presented similar Z-potentials in water and PBS
[24,29,30] (CCL660: −17.1 ± 3.1mV and− 2.3 ± 0.3mV and
CCLSCR: −18.5 ± 1.3mV and− 1.6 ± 0.2, respectively), indicating
good stability in medium resembling physiological conditions (Table 1).
These parameters warrant and justify the loss of aggregation during
lipid-nanoparticles storage and increase the half-life under systemic
conditions, as expected due to the presence of the polyethylene glycol
(PEG) shield [31].
2.2. CCL660 administration reduces tumor growth in P53 wild type models
We subcutaneously implanted PDX samples into SCID mice and
assessed the miRNA biodistribution after 1 (at t=24 h after tumor
implantation) or 2 (at t= 24 h and t=96 h after tumor implantation)
intravenous (i.v.) or intraperitoneal (i.p.) injections of CCLs (1.5 mg/Kg)
(n=3 animals per group) to evaluate the eﬃcacy of the delivery of the
lipidic miRNA nanoparticles. The digital PCR (dPCR) analysis revealed
4- and 3-fold increases in the miRNA levels in tumors after single i.p.
and i.v. injections, respectively. The double treatment conﬁrmed the
presence of higher levels of the liposomal compound both in tumors and
plasma than in untreated animals (Fig. S1).
Next, we tested the eﬃcacy of the CCL660 treatment in PDX305,
PDX73 (both P53wt) and PDX111 (P53mut) by administering the
miRNA entrapped in the lipidic-nanoparticles formulation (1.5 mg/Kg)
i.p. twice a week for four weeks. The PDX samples were subcutaneously
implanted into SCID mice, and treatment was started when the tumors
reached 100–150mm3 in volume (7/8 days after cell inoculation).
Interestingly, an appreciable reduction in tumor volume was observed
at 42 days in P53wt PDXs (25% for PDX305 and 47% for PDX73 re-
duction in the volume of CCL660-treated tumors compared with that of
vehicle-treated tumors, Fig. 1A-B), whereas the P53-mutated PDX111
was not aﬀected by the CCL660 treatment (Fig. 1A-B). Furthermore, we
treated PDX models also with lipid-nanoparticles encapsulating a ne-
gative-scrambled sequence (CCLSCR) to conﬁrm that the anti-tumor
eﬀects of CCL660 were due to miR-660 activity without observing
variation in tumor growth compared with the HEPES controls (n=4
animals per PDX305 and PDX11; n=6 for PDX73) (Fig. 1A-B).
Based on these data, the lipidic-nanoparticles miRNA formulation
reached PDXs growing subcutaneously in immunocompromised mice,
and CCL660 impaired tumor growth in a P53-dependent manner.
2.3. CCL660 induces cell cycle arrest by modulating MDM2 levels
We examined miR-660 expression in mouse organs and tumor cells
using dPCR to determine whether the anti-tumor activity of the miRNA
was responsible for the observed reduction in tumor growth. In
CCL660-treated tumors, miR-660 expression was increased by 20-, 5-
and 2.5-fold compared with that in control mice, in PDX305, PDX73
and PDX111, respectively (Fig. 2A). In addition, miRNA accumulation
was observed in the liver, lung, spleen and plasma, consistent with the
ﬁndings of previous miRNA delivery studies [32] (Fig. 2A).
Moreover, miRNA in situ hybridization (ISH) analysis conﬁrmed an
increase in miR-660 expression in CCL660-treated tumors compared
with that in controls (CCLSCR- and vehicle- treated) tumors in both
Table 1
Physico-chemical characterization of CCLs.
Sample Size Z-potential [mV]
Diameter [nm] PdI H2O PBS
CCLSCR 123 ± 5 0.095 ± 0.019 −18.5 ± 1.3 −1.6 ± 0.2
CCL660 121 ± 6 0.092 ± 0.018 −17.1 ± 3.1 −2.3 ± 0.3
Table 1 The sizes and Z-potentials of CCLSCR and CCL660 were determined
using a particle size analyzer. The PdI indicates the homogeneity of the samples
in terms of size distribution. The value ranges from zero (good preparation) to
one (bad formulation). Z-potential in H2O represents the real charge of the
particles, as well as their aggregation potential. Z-potential in PBS indicates the
charge of the particles under physiological conditions. The results are presented
as means of triplicate reading of each lipid-nanoparticles± standard devia-
tions.
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PDX models (28%,30% and 26% miR-660-positive cells in animals
treated for PDX305, PDX73 and PDX111, respectively, compared with
10% endogenous miR-660-positive cells in the controls (CTR and
CCLSCR) for both models; p < .05) (Fig. 2B and Fig. S2). Im-
munohistochemical (IHC) staining for Ki-67 was evaluated at 42 days
and showed a reduction in the mitotic index of CCL660-treated tumors
compared with that of the controls, according to the P53 status
(32%,15% and 0% reduction in the number of Ki-67-positive cells in
PDX305, PDX73 and PDX111, respectively) (Fig. 2B and Fig. S2).
Since the MDM2 mRNA is a direct target of miR-660, we evaluated
MDM2 expression using real-time PCR and observed 40%, 80% and
50% reductions in PDX305, PDX73 and PDX111, respectively (Fig. 2C).
A concomitant increase in P53 and P21 mRNA expression was observed
in P53wt CCL660-treated tumors compared to controls (p < .05). De-
spite the observed MDM2 down-regulation in PDX111 (P53mut model),
P21 transcription was not aﬀected, conﬁrming that a wild-type P53
gene is required for the anti-tumor activity of miR-660 (Fig. 2C). The
modulation of MDM2/P53 axis after CCL660 was conﬁrmed by IHC
analysis showing MDM2 modulation and P53 and P21 up-regulation
(Fig. 2D and Fig. S2). MDM2 protein was not detected by IHC in
PDX305 and PDX111 as already described [33].
2.4. Long- lasting treatment increases the CCL660-mediated inhibition of
tumor growth
We treated another PDX model, PDX302, carrying a P53 mutation
responsible for P53 traﬃcking into mitochondria but with a functional
p21 pathway, with CCL660 (1.5 mg/Kg) i.p. twice a week for 8 weeks to
investigate whether eﬃcacious miR-660 delivery was achieved by in-
creasing the duration of treatment and to conﬁrm the dependency of
the eﬀects of CCL660 on the presence of a wild-type P53 gene.
Interestingly, a 50% reduction in the tumor volume was observed in
treated mice compared with controls at 68 days (volume: 133 ± 15,
244.6 ± 38 and 250 ± 50mm3 in CCL660-treated, CCLSCR-treated
and control tumors, respectively, p < .05; Fig. 3A and B). According to
the dPCR data, CCL660 reached tumors, as a 7-fold increase in the miR-
660 levels was observed in the treated groups compared with controls.
Accumulation of miR-660 was also observed in the spleen, liver, lungs
and plasma of treated mice (Fig. 3C). Furthermore, higher miR-660
expression was observed in the tumors using miRNA ISH (22%, 5% and
3% miR-660-positive cells in CCL660-treated and control tumors, re-
spectively; p < .05) and a reduction in the number of Ki-67 positive
cells in CCL660-treated tumors was observed using IHC (36% reduction
in the number of Ki-67-positive cells compared with that in controls;
p < .05; Fig. 3D and Fig. S2) were observed.
Fig. 1. CCL660 reduces tumor growth in P53wt models. A) Tumor growth curves of PDX305 (n=6 for CTR and CCL660, n=4 for CCLSCR, left panel), PDX73
(n=8 for CTR and CCL660, n= 6 for CCLSCR centre panel) and PDX111 (n=7 for CTR and CCL660, n= 4 for CCLSCR, right panel) treated with CCL660 (1.5 mg/
kg) for 4 weeks. The black arrow indicates the day on which treatment began B) Graphs show the tumor volumes at the end of CCL660 treatment (42 days) compared
with those in control mice (both CTR and CCLSCR). Data are presented as means± S.E.M. * p < .05 (One-way ANOVA test comparing CCL660 vs CTR or CCLSCR).
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CCL660 downregulated the expression of the MDM2 mRNA, as as-
sessed by real-time PCR, with concomitant increase in the transcription
of P53 and its eﬀector, the P21 protein (Fig. 3E). Interestingly, a
decrease in the levels of the MDM2 protein (44% reduction in MDM2
levels in treated mice compared to those in controls; p < .05) (Fig. 3F)
and up-regulation of P53 and P21 protein were detectable by IHC after
Fig. 2. CCL660 induces cell cycle arrest by modulating MDM2 expression. A) Graphs of dPCR data show miR-660 accumulation in tumors and other organs from mice
transplanted with PDX305 (left panel), PDX73 (centre panel) and PDX111 (right panel). B) Representative images of miR-660 ISH and Ki-67 staining in PDX tumors
after CCL660 treatment. C) Graphs of real-time PCR data show MDM2 down-regulation and increased P53 and P21 expression in PDX305 (left panel) and PDX73
(centre panel), whereas only reduced MDM2 expression was observed in PDX111 (right panel) (n=6 for CTR and CCL660, n=4 for CCLSCR for PDX305; n=7 for
CTR and CCL660, n= 6 for CCLSCR for PDX111 and n=8 for CTR and CCL660, n= 6 for CCLSCR for PDX73). D) Representative images of MDM2, P53 and P21
staining in PDXs after CCL660 treatments (42 days). Data are presented as means± S.E.M. * p < .05 (One-way ANOVA test comparing CCL660 vs CTR or CCLSCR).
M. Moro, et al. Journal of Controlled Release 308 (2019) 44–56
47
CCL660 treatment, supporting that hypothesis that miR-660 induced
cell cycle arrest in tumor cells (Fig. 3F).
2.5. CCL660 does not induce side eﬀects on normal tissues and cells
The evidence that CCL660 administration increased levels of miR-
660 also in non-target organs, such as lung, liver and spleen, prompted
us to investigate whether miRNA over-expression could have side ef-
fects on normal tissues. In this regard, it is worth mentioning that
though human hsa-miR-660 is not conserved in the mouse, a murine
miRNA having the same seed sequence as miR-660 exists, namely mmu-
miR-6987 (Fig. 4A). The two miRNAs are hence expected to share part
of their targets, provided that the latter have conserved binding se-
quences in their 3’UTRs. This is the case of MDM2, because murine
Fig. 3. Long lasting treatment increases the anti-tumor eﬀects of CCL660. A) Tumor growth for PDX302 treated with CCL660 (1.mg/kg) for 8 weeks. The black arrow
indicates the day on which treatment began. B) Graphs show reduced tumor volumes in CCL660-treated mice compared to those in CCLSCR and CTR mice. C) Graphs
of dPCR data show miR-660 accumulation in tumors and other organs in treated mice. D) Representative images of miR-660 ISH and Ki-67 in PDX after CCL660
treatment. E) Real-time PCR data illustrating MDM2 downregulation and increased P53 and P21 expression F) MDM2, P53 and P21 IHC expression on PDX treated
with CCL660 or CCLSCR or CTR (n=4 for CTR, n=5 for CCLSCR and n=6 for CCL660). Data are presented as means± S.E.M. * p < .05 (One-way ANOVA test
comparing CCL660 vs CTR or CCLSCR).
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Fig. 4. MiR-660 did not induce side eﬀects in normal tissues. A) Mdm2 3′ UTR-binding site for mmu-miR-6987. B) Mdm2 mRNA levels in mouse organs treated with
CCL660 or control (n=10). C-D) Proliferation (C) and apoptotic (D) graphs of human cell lines transfected with miR-660 or mimic control (50 nM, n=5 for each
assay). E-F) MiR-660 over-expression did not induce any changes of proliferation (E) and apoptosis (F) in murine cell lines. Data are presented as means± S.E.M. *
p < .05.
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ortologue Mdm2 is predicted to be target of both human miR-660 and
murine miR-6987 (Fig. 4A). Since miR-660 could potentially bind
murine Mdm2, we analyzed Mdm2 mRNA expression in healthy tissues
from mice treated with CCL660 and observed a statistical signiﬁcant
reduction of Mdm2 expression in lung, liver and spleen (Fig. 4B). De-
spite this, CCL660 did not induce any major side eﬀects on such organs,
as evidenced by organ weight and immune cell inﬁltrates analysis
performed after 4 weeks of CCL660 treatment in immunodeﬁcient mice
(Fig. S3A-B).
The safety of the cationic lipid DOTAP for the cells has been pre-
viously demonstrated in vitro and in vivo for asODNs and siRNAs
[24,25,34,35]. To conﬁrm the evidence that normal cells well tolerate
miR-660 over-expression, we analyzed proliferation rate and apoptosis
in various cell types both from human and mice after miRNA trans-
fection. In particular, we selected non tumorigenic human bronchial
epithelial cells (HBEC-1), human kidney cells (HEK293), human hepatic
stellate cells (LX-2), human endothelial cells (HUVEC) and primary
human macrophages from healthy donors.
As shown in Fig. 4C we did not observe any signiﬁcative changes in
cell proliferation at 72 and 120 h after miR-660 transfection for all the
cells analyzed. Furthermore, we evaluated apoptosis by measuring the
AnnexinVpos/PIneg cells in miR-660 over-expressing cells without ob-
serving changes in the number of apoptotic cells after 72 h compared to
cells transfected with mimic control (Fig. 4D). MiR-660 over-expression
did not induce any signiﬁcative changes in proliferation and apoptosis
also in mouse liver, kidney and macrophage cells (Fig. 4E-F).
Overall, these ﬁndings let speculate that though CCL660 delivers
miR-660 also to non-target organs and cells, normal cells are somehow
tolerant to miR-660-induced MDM2/Mdm2 down-regulation.
Furthermore, our results show that MDM2 inhibition is selective and
induces p53-dependent cell death only in tumor cells as already de-
scribed for Nutlin and other small MDM2 inhibitors [36].
2.6. CCL660 does not induce immune-related toxic eﬀects
It is known that liposomal compounds may have immune-related
toxic eﬀects [37]. To assess the acute in vivo toxicity of our lipidic ve-
hicles we injected i.p. HEPES-buﬀered saline alone (CTR) or a single
dose (1.5 mg/kg) of miR-660 or miR-SCR entrapped in lipidic nano-
particles (CCL660 or CCLSCR) into immunocompetent mice (n=3
animals per group) and evaluated blood biochemistry, organ weight,
immune cell inﬁltrates in organ tissues, and chemokine, cytokine and
growth factor production [38].
As shown in Fig. 5A-B,H&E staining did not reveal any signs of in-
ﬂammation in the organs, and no signiﬁcant changes occurred in im-
mune subpopulations in CCL660-treated mice compared with those in
controls. Furthermore, no variations in the body and organ weights
were observed in mice treated with lipid-nanoparticles, again con-
ﬁrming that our lipidic vehicles did not exert any apparent toxic eﬀects.
Blood biochemical analyses of metabolites (alanine transaminase
(ALT), aspartate transaminase (AST), azotemia, glucose and creatinine)
did not reveal signiﬁcant diﬀerences between CCL660 and the control
(Table 2), indicating that lipid-nanoparticles did not exert toxic eﬀects
on the liver and kidney of treated mice.
We also performed a plasma cytokine array to detect levels of 22
pro-inﬂammatory cytokines, and no changes in the levels of these
proteins were observed in mice treated with CCL660 or CCLSCR, ex-
cluding major eﬀects of the lipid-nanoparticles on the activation of the
immune system (Fig. 5C).
To exclude potential chronic toxic eﬀects, we analyzed blood bio-
chemistry, organ weight, immune cell inﬁltrates in organ tissues, and
cytokines after 4 weeks of CCL660 treatment in immunocompetent
mice (n=5 animals per group).
The necropsy results did not reveal any macroscopic changes in the
organs of mice after 4 weeks of CCL660 treatment and the results of the
histopathological analysis and the organ weight assessments did not
show changes in any of the mice treated with CCL660 (Fig. 4D-E). Blood
metabolites and cytokine analysis did not reveal any modulations after
nanoparticles treatments conﬁrming the absence of chronic toxic eﬀects
of our compounds (Table 3 and Fig. 4F).
2.7. MiR-660 inhibits cancer growth in a lung colonization model
Since our PDXs models didn't disseminate eﬃciently to the lungs to
form visible lung nodules [39], we established a lung colonization assay
in immunocompromised mice to prove the eﬃcacy of miR-660 in in-
hibiting lung cancer growth also in an orthotopic model of lung cancer.
Speciﬁcally, we i.v. injected SCID mice with 1× 106 H460 lung cancer
cells that had been stably transfected with miR-660 (H460-miR-660) or
a scrambled sequence (H460-miR-CTR) as a control, and monitored
lung nodule growth using an 18F-FDG animal PET analysis. Interest-
ingly, 28 days after cells were injected, 18F-FDG uptake was observed in
the lungs of H460-injected mice, but not H460-miR-660 mice (Fig. 6A,
upper panels). Moreover, an ex vivo PET analysis of mouse lungs
showed decreased 18F-FDG uptake in H460-miR-660-injected mice
compared with that in H460 control-injected mice (Fig. 6A, lower pa-
nels). H&E and pan-cytokeratin staining conﬁrmed a reduction in lung
nodule growth in miR-660-overexpressing H460 tumors compared with
that in controls (Fig. 6B-C). In fact, only one nodule was detected in the
lungs of H460-miR-660-treated mice. Furthermore, we performed ISH
to analyze the expression of miR-660 and observed that miR-660 was
not expressed in H460-miR-CTR mice, whereas only a few miR-660
positive cells were observed in the treated group (Fig. 6B). IHC staining
for MDM2 conﬁrmed the inverse correlation between miR-660 ex-
pression and staining for the MDM2 protein. Interestingly, the lung
nodules observed in H460-miR-660-treated mice did not express this
miRNA in tumor cells and exhibited MDM2 levels similar to control
cells, indicating that miR-660 expression was lost, allowing tumor
growth in the lung (Fig. 6B-C).
3. Discussion
The rationale for the use of miRNA mimics in lung cancer is based
on the evidence that miRNAs are deregulated and involved in lung
cancer development [40] and that miRNA replacement in cancer cells
reverts their aggressive phenotype [41]. As shown in our previous re-
port, miR-660 is down-regulated in lung cancer tissues, and the over-
expression of this miRNA in tumor cells reduces their migration and
proliferation. The anti-tumor activity of miR-660 was mediated by
down-regulating MDM2 and restoring P53 function [18].
Here, lipid-nanoparticles delivery of miR-660 reduced the tumor
growth of lung cancer PDXs by inducing cell cycle arrest in a P53-de-
pendent manner. Interestingly, in a P53-mutated PDX model, we did
not observe changes in tumor proliferation, although we observed re-
duced MDM2 expression in the P53 wild-type models, conﬁrming the
importance of a functional P53 gene for the anti-cancer activity of miR-
660. In particular, anti-tumoral eﬀects of CCL660 on PDX302 carrying a
P53 mutation, suggested that miR-660 could be also used to treat P53
mutated tumors with a functional p21 pathway.
In our previous study, H460 lung cancer cells injected i.v. into SCID
mice invaded the lung parenchyma and produced fully developed no-
dules, starting from a particular cellular subset endowed with a high
seeding potential [39]. Our preliminary data show in a similar lung
colonization assay, that miR-660 counteracted H460 nodule formation,
suggesting that either miR-660 has a role in the processes underlying
nodule development after the seeding of tumor cells in distant organs or
a direct eﬀect on the seeding process of circulating cells.
Lipid-nanoparticle systems are one of the most promising vectors for
miRNA delivery. However, cationic liposomes were reported to be
highly immunogenic due to the interactions between the positively
charged lipids and proteins. Interferon-γ responses have been described
after liposomal treatments [42].
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Evidence of miRNA replacement as an eﬀective therapy for lung
cancer in genetically modiﬁed mouse models was provided for let-7 and
miR-34 [43], and the ﬁrst compound based on miRNA mimics to enter a
phase I clinical trial was MRX34, a liposomal miR-34 mimic compound
tested in patients with liver cancer, other solid tumors and hematolo-
gical diseases to assess pharmacokinetics and pharmacodynamics [44].
This trial was prematurely terminated because severe immune-related
events causing patient deaths were recorded. The adverse events of
MRX34 administration were related to pro-inﬂammatory changes and
macrophage activation, which were potentially attributable to the li-
posome carrier and not the miR-34 mimics [45]. Based on this negative
result, pre-clinical investigations of possible immune-related toxicity
are required. Noteworthy, the lipid-nanoparticles herein used are a
neutral lipid coated formulation identical, in the exterior surface, to
that used to deliver asODNs, and siRNAs without any immunological-
induced toxicities [24,25,34]. However, in the present study, we
Fig. 5. CCL660 does not induce acute and chronic immune-related toxic eﬀects. A) Representative H&E staining of immune inﬁltrates in mice injected with single
dose (1.5 mg/kg) for 24 h of lipid-nanoparticles. B) Graphs show body and organ weights of CCLSCR- and CCL660-treated mice compared with controls. C) Bar
graphs illustrate plasma pro-inﬂammatory cytokine levels in the CCL-treated mice (n=3 mice per group). D) Representative H&E staining of immune inﬁltrates in
mice injected with lipid-nanoparticles after 4 weeks of treatment. E) Graphs show body and organ weights of CCL660-treated mice compared with controls. F) Bar
graphs illustrate plasma pro-inﬂammatory cytokine levels in the CCL660 (1.5 mg/kg) treated mice twice after 4 weeks of treatment (n=5 mice per group). Data are
presented as means± S.E.M. * p < .05.
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analyzed potential immune-related events after single or prolonged
administration of CCL660 in immunocompetent mice, and did not ob-
serve modulation of acute inﬂammatory cytokines such as IFN-α or
TNF-α compared to control animals. Long-term treatment of lipid-na-
noparticles entrapping miR-660 didn't modulate plasma levels of sev-
eral pro-inﬂammatory cytokines suggesting an absence of toxicity ef-
fects. Interestingly, histopathological analysis of the mouse organs after
single and long-term treatments revealed that CCL660 didn't increase
the immune cells inﬁltration in tissues excluding any signs of chronic
toxicity.
Despite the encouraging results regarding toxicity, CCL660 only
partially decreased tumor growth in P53 wild-type PDXs, and miRNA
ISH revealed that CCL660 only reached 30% of lung cancer cells, thus
lacking a uniform distribution in the tumor samples. This low delivery
eﬃciency, which is likely related to rapid clearance or phagocytosis of
the liposomal compound by immune cells [37], could explain the lim-
ited inhibitory eﬀects on tumor growth observed in our PDX models.
Lipid-nanoparticles represent an eﬀective drug delivery system that
is capable of altering the pharmacokinetic proﬁle of a drug and deli-
vering the encapsulated agent [46]. One potential strategy to improve
the therapeutic eﬃcacy of the miRNA mimics and to reduce non target
toxicity is to modify lipid-nanoparticles by adding a tumor cell-speciﬁc
ligand on the lipid surface.
Indeed, the combination of the pharmacokinetic advantages and
tumor-selective biodistribution of lipid-nanoparticles with cell-speciﬁc
binding and internalization induced by antibodies or receptor ligands is
a recognized strategy to improve the therapeutic eﬀectiveness of con-
ventional chemotherapeutics or gene therapeutics for treating human
malignancies, including lung cancer [26,47,48].
The availability of ligands or peptides or tumor-associated antigens
would enable researchers to design more sophisticated cancer treat-
ment strategies that exhibit high levels of selective toxicity for cancer
cells [49].
Therefore, new candidate lung cancer cell-speciﬁc ligands must be
identiﬁed to improve the therapeutic outcomes, decrease side eﬀects
and improve patients' quality of life.
Systemic delivery is the most feasible route for the use of miRNAs in
the clinic, but the main challenge is the low uptake of the delivered
miRNAs in lung cancer cells [50]. The development of new delivery
systems, such as inhaled liposomes, may be a valid option to overcome
this issue, particularly for lung cancer treatment [51]. The success of
this method will depend on the development of new aerosol devices and
the formulation of eﬃcient inhalable liposomes.
Recently, the discovery that exosomes are secreted into body ﬂuids
and their ability to be loaded with miRNAs oﬀered a new and inter-
esting approach for miRNA delivery [52]. In addition, these micro-
vesicles allow the cargo to escape from phagocytosis and are endowed
with an increased half-life in the circulation compared to liposomes
[53]. Thus, exosomes loaded with selected miRNAs represents an al-
ternative and potentially valid therapeutic strategy for treating lung
cancer.
Although challenges regarding eﬃcient miRNA delivery persist, our
experiments with lipid-nanoparticles entrapping miR-660 in preclinical
mouse models showed promising results both in terms of tumor growth
inhibition and the absence of toxic eﬀects. However, future studies in
pre-clinical models comparing the treatment with cationic lipid-nano-
particles carrying miR-660 with the standard of care for lung cancer
patients or adding a tumor cell-speciﬁc ligand on the lipid surface to
improve the therapeutic eﬃcacy of the miRNA mimic and to reduce
non target toxicity are needed. Overall, the present study provides new
insights into the development of miRNA delivery systems as treatments
for lung cancer.
4. Materials and methods
4.1. Reagents and chemicals
4.1.1. Lipids
Hydrogenated soy phosphatidylcholine (HSPC), cholesterol (CHE),
1,2-distearoylsn-glycero-3-phosphoethanolamine-N-[methoxy (poly-
ethylene glycol)-2000] (DSPE-PEG2000), and 1,2-dioleoy-1-3- ri-
methylamonium propane (DOTAP) were purchased form Avanti Polar
Lipids, Inc. (Alabaster, AL, USA).
miRVana™ miRNA Mimic Negative Control #1 (miR-NC1) and
miRVana™ miRNA mimic miR-660 (miRNA ID# MC11216) for lipid-
nanoparticles preparations were purchased from Ambion (Thermo
Fisher Scientiﬁc, Waltham, MA, USA).
Nucleopore polycarbonate membranes were purchased from
Avestin Inc. (Ottawa, ON, Canada). Sephadex G-50 was purchased from
PerkinElmer Biosciences (Waltham, MA, USA).
All other reagents were of analytical grade or the highest available
purity and were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Table 2
Acute liver and renal toxicity studies.
ASTa (IU/L) ALTb (IU/L) CREc (mg/dL) Azotemia (mg/dL) Glucose (mg/dL)
CTR 123.5 ± 52.3 55.3 ± 17.8 0.02 ± 0.01 29.8 ± 3.6 111 ± 10.5
CCLSCR 116 ± 53 32 ± 17.01 0.021 ± 0.012 26.3 ± 1.4 119.5 ± 11.9
CCL660 82.3 ± 19.5 25 ± 15 0.019 ± 0.01 28.6 ± 5.2 114 ± 16.5
Blood samples collected 18 h after i.p. injections of CCLSCR or CCL660 or HEPES-buﬀered saline alone (CTR) were quantiﬁed to determine the serum levels of
a Aspartate Aminotransferase (AST),
b Alanine Aminotransferase (ALT),
c Creatinine (CRE), Azotemia and Glucose. Data are presented as means± S.D.
Table 3
Chronic liver and renal toxicity studies.
ASTa (IU/L) ALTb (IU/L) CREc (mg/dL) Azotemia (mg/dL) Glucose (mg/dL)
CTR 102.4 ± 43.9 67.3 ± 18.5 0.024 ± 0.017 32.8 ± 7.6 101.6 ± 26.8
CCL660 77.6 ± 15.1 60.3 ± 28.6 0.020 ± 0.003 31.6 ± 5.2 116 ± 2.2
Blood samples collected 16 h after the i.p. injection of 8 treatments (chronic toxicities) were quantiﬁed for serum levels of
a Aspartate Aminotransferase (AST),
b Alanine Aminotransferase (ALT),
c Creatinine (CRE), Azotemia and Glucose. Data are presented as means± SD.
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4.2. Cell lines
Human bronchial epithelial (HBEC-1), kidney (HEK293), hepatic
stellate cells (LX-2), endothelial cells (HUVEC), H460 lung cancer,
murine JS-1, NIH-3 T3 and RAW264.7 cell line (ATCC or Merck, USA)
were cultured in appropriate medium. Primary human macrophages
from healthy donors were obtained as described [54]. Stable miR-660-
overexpressing H460 cells were obtained using methods described in a
previous study [18].
4.3. Cells assay
Cells were seeded in a 6-well plate and transfected with 50nM of
miR-660 mimic or negative control (SCR) using Lipofectamine 2000
(Thermo Fisher Scientiﬁc) following manufacturer's protocols.
For proliferation assay cells were seeded in a 96 well plate at
2× 103 cells and ﬂuorescence were measured after 72 and 120 h using
RealTime-Glo MT Cell Viability Assay (Promega). Each experiment was
performed in quintuplicate.
Apoptosis was measured by quantifying the percentage of Annexin
Vpos/Propidium Iodideneg cells by ﬂow cytometry as previously de-
scribed [18].
4.4. Preparation of CCLs
Small, stable Coated Cationic Lipid-nanoparticles (CCLs) entrapping
miRNA-NC1 (CCLSCR) or miRNA-660 (CCL660) were prepared and
puriﬁed as previously described [24,25]. Brieﬂy, the DOTAP amount is
modiﬁed according to the number of negative charges of synthetic
antisense oligonucleotides, siRNA and miRNA [24,25,27,34]. Lipid-
nanoparticles were sequentially extruded through 400 nm, 200 nm and
100 nm polycarbonate ﬁlters. Non-entrapped miRNAs were removed
using a Sephadex G-50 column that had been pre-equilibrated with
HEPES-buﬀered saline (25mmol/L HEPES, 140mmol/L NaCl, pH 7.4).
The amount of miRNAs encapsulated in CCLs was evaluated by solu-
bilizing lipid-nanoparticles preparations with 40mmol/L sodium
deoxycholate for 1.5 h at room temperature followed by spectro-
photometer measurement at 260 nm [24,25]. The percentage of en-
trapped miRNAs was assessed by ﬂuorescence-activated cell sorting
(FACS) analysis as described and modiﬁed by us [24]. The particle size
hydrophobic diameter (in nm), polydispersity index (PdI) and zeta
potential (Z-potential in mV) of the lipidic nanoparticle preparations
were measured using a Malvern Nano ZS90 light scattering apparatus
(Malvern Instruments Ltd., Worcestershire, UK). The parameters set for
analyses were a scattering angle of 90° and a temperature of 25°C
Fig. 6. MiR-660 inhibits cancer growth in lung co-
lonization models. A) PET analysis of mice 28 days
after the injection of 1× 106 H460 lung cancer cells.
Upper panels show representative axial sections of
18F-FDG uptake in the lungs of mice injected with
H460 (left panel) and H460-miR-660 cells (middle
and right panels). H and L indicate the mouse heart
and lung, respectively. Lower panels show the re-
sults of the ex vivo PET analysis of lungs from mice
injected with H460-miR-CTR (left panel) and H460-
miR-660 cells (middle and right panels). B)
Representative images of H&E and pan-cytokeratin
staining of the lungs from H460-miR-660-injected
mice and control mice. The results revealed an in-
verse correlation between miR-660 and MDM2 levels
in the lungs (n=2 mice per group).
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[24,25,29,55]. Z-potential values were recorded following dilution in
distilled water or PBS. The results from the light scattering experiments
are presented as average values of triplicate reading of each lipid-na-
noparticle preparations used± standard deviations.
4.5. PDXs and in vivo assays
PDXs were established as previously described [56]. Mice were
maintained in the Animal Facility of Fondazione IRCCS Istituto Na-
zionale dei Tumori. Animal experiments were authorized by the In-
stitutional Animal Welfare Body and Italian Ministry of Health and
were performed in accordance with national laws (D.lgs 26/2014).
Regarding the TP53 mutational status we proﬁled our PDX models and
observed that PDX111 had P53p.C242X mutation whereas PDX302 had
P53p.C135Y mutation that it is described a mutation important for
mitochondrial traﬃcking of P53 [57].
Experiments were conducted using SCID mice (Charles River
Laboratories, Lecco, Italy) bearing a PDX tumor in one ﬂank. Mice were
i.p or i.v. injected with 1.5 mg/Kg of the miR-660- or miR-SCR-en-
trapped lipid-nanoparticles (CCL660 or CCLSCR, respectively) or
HEPES-buﬀered saline as the control (CTR) twice a week for four or
eight weeks. Each time mice received a total volume of 200 μL of freshly
diluted solution of lipid-nanoparticles in HEPES-buﬀered saline or
200 μL of HEPES-buﬀered saline alone. Dose and schedule of treatment
was selected according to literature [58,59]. Tumor growth was mon-
itored weekly using calipers, and the results were analyzed using
GraphPad Prism 5 software (GraphPad Software, San Diego, CA, USA).
18F-FDG PET analyses were performed on isoﬂurane-anesthetized
SCID mice. Brieﬂy, the mice were injected with 200 μL of 18F-FDG
(100MBq) in an injectable solution. Forty-ﬁve minutes after the injec-
tion, the mice were analyzed using the PETGE Explore Vista system
(General Electric Healthcare, Chalfont St. Giles, UK) for 20min. At the
end of the PET analysis, the mice were sacriﬁced, and lungs were re-
moved and immediately analyzed for 18F-FDG uptake ex vivo.
4.6. Analysis of miRNA and mRNA expression in tissues
PDXs and mouse tissues were ﬁrst homogenized using 3mm
Tungsten Carbide Beads and the Mixer Mill MM300 (Qiagen, Hilden,
Germany), and then total RNA was extracted using the automatic
Maxwell RSC Instrument (Promega, WI, USA) and commercially
available kits (Qiagen), according to the manufacturers' instructions.
Next, 20 ng of total RNA were reverse transcribed into cDNAs by per-
forming multiplex reverse transcription PCR (RT-PCR) using the
TaqMan MicroRNA Reverse Transcription Kit (Thermo Fisher) and a
TaqMan RT Primer Pool with the miRNAs of interest (Thermo Fisher).
dPCR was performed as described by Conte et al. [60].
For gene expression analyses, reverse transcription was performed
using 250 ng of total RNA. The TaqMan microRNA assay (Thermo
Fisher) and ready-to-use Assay on Demand (Thermo Fisher) were used
with a QuantStudio 7 Flex System (Thermo Fisher) to analyze the ex-
pression of selected genes, and the human GAPDH gene was used as a
reference for sample normalization.
4.7. ISH analysis of miRNAs
The protocol for miR-660 ISH on PDX and mouse tissues is based on
a combination of double DIG-conjugated mirCURY locked nucleic acid
(LNA) probes (Exiqon, Vedbæk, Denmark) and a Tyramide Signal
Ampliﬁcation (TSA) DAB-chromogenic detection system (Perkin Elmer
System) that together enable the speciﬁc and sensitive detection of
miRNAs. Probe selected for ISH analysis is listed in Table 4. For image
analysis, stained sections were examined under an optical microscope
and scanned with AperioScanscope XT (Leica Biosystems, Nussloch,
Germany). For miRNA quantiﬁcation three random ﬁelds (Magniﬁca-
tion: 30×) for each slides were analyzed counting the number of
positive cells relative to the number of total tumoral cells.
4.8. Immunohistochemical (IHC) staining
H&E staining and levels of the Ki-67 antigen and MDM2 protein
were investigated using IHC. Brieﬂy, 2.5/3 μm-thick sections were cut
from paraﬃn blocks, dried, de-waxed, rehydrated, and unmasked (with
Dako PT-link, EnVision FLEX Target Retrieval Solution, High Ph, Dako,
Denmark). A Ki-67 monoclonal antibody (Clone MIB 1 Dako, dilution
1:400) and anti-MDM2 monoclonal antibody (Calbiochem; Merck
Millipore; OP 46, dilution 1:60) were incubated in an automated im-
munostainer (DakoAutostainer System) using a commercially available
detection kit (EnVision FLEX+, Dako). For each slide, positive cells
were counted in 3 random ﬁelds at 30× magniﬁcation using an Aperio
Scanscope XT (Leica Biosystems).
4.9. Determination of kidney and liver toxicity
Balb/c mice were purchased from Envigo (Envigo, S. Pietro al
Natisone, Italy) and were housed under pathogen-free conditions; the
experiments were reviewed and approved by the licensing and ethical
committee of the IRCCS Azienda Ospedaliera Universitaria San
Martino-IST Istituto Nazionale per la Ricerca sul Cancro (Genoa, Italy)
and by the Italian Ministry of Health.
Mice were i.p. injected with a single dose (1.5 mg/Kg) of miR-660 or
miR-SCR entrapped in CCL or HEPES-buﬀered saline alone (CTR). For
chronic toxicity studies mice were treated i.p. twice a week for 4 weeks
with 1.5mg/Kg of CCL660 or HEPES-buﬀered saline alone. Each time
mice received each times a total volume of 200 μL of freshly diluted
solution of lipid-nanoparticles in HEPES-buﬀered saline or 200 μL
HEPES-buﬀered saline alone. Eighteen hours after one or eight treat-
ments, mice were sacriﬁced, blood was collected, and organs were ex-
cised. Livers, spleens, and lungs were weighed, ﬁxed overnight with
formalin, and then embedded in paraﬃn. Paraﬃn-embedded tissue
sections were prepared as described above and then stained with H&E
to evaluate the immune inﬁltrates in mice injected with lipid-nano-
particles.
Blood samples were harvested in tubes containing sodium citrate
and then centrifuged at 1000× g for 15min at 4 °C. Plasma levels of
Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT),
Creatinine (CRE), azotemia and glucose were quantiﬁed as indicators of
liver and kidney toxicity. The analyses were performed using the Cobas
E6000 analyzer (Roche Diagnostics, Monza, Italy).
4.10. Cytokine, chemokine and growth factor quantiﬁcation
The plasma derived from single dose -treated mice was also ana-
lyzed using the Bio-Plex Pro Assay (Bio-Rad Laboratories S.r.l, Milan,
Italy) to determine the levels of the following cytokines: G-CSF (gran-
ulocyte colony-stimulating factor), GM-CSF (granulocyte-macrophage
colony-stimulating factor), IFN-γ (interferon gamma), IL-1α (interleukin
1 alpha), IL-1β (interleukin 1 beta), IL-2 (interleukin 2), IL-4 (inter-
leukin 4), IL-5 (interleukin 5), IL-7 (interleukin 7), IL-9 (interleukin 9),
IL-10 (interleukin 10), LKI (lipopolysaccharide-inducible CXC chemo-
kine), IL-15 (interleukin 15), IL-17 (interleukin 17), IP-10 (interferon
gamma-induced protein 10), KC (mouse keratinocyte-derived cyto-
kine), MCP-1 (monocyte chemoattractant protein 1), MIP-1α
Table 4
Detection probe.
Probe RNA Tma (°C) T hybb (°C) Probe sequence
Hsa-miR-660 86 54 CAACTCCGATATGCAATGGGTA
a Tm: melting temperature;
b T hyb: hybridization temperature.
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(macrophage inﬂammatory protein 1 alpha), MIP-1β (macrophage in-
ﬂammatory protein 1 beta), MIP-2 (macrophage inﬂammatory protein
2), RANTES (regulated upon activation, normal T cell expressed and
secreted), and TNF-α (tumor necrosis factor alpha). The assay was
performed using Luminex Technology by Bioclarma S.r.l. (Turin, Italy),
according to the manufacturer's instructions.
Analysis of 12 cytokines levels (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-
10, IL-12, IL-13, IL-17a, G-CSF, GM-CSF) in plasma mice treated for
4 weeks with CCL660 or control was performed using Mouse Common
Cytokines multi-Analyte ELISArray Kits following manufacturer's in-
struction (Qiagen). The absorbance at 450 nm was read using Inﬁnite
M1000 (Tecan, GmbH, Grodig/Salzburg, Austria).
5. Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 soft-
ware. Results are presented as mean values± standard deviations
(S.D.) and/or standard errors of the means (S.E.M.) for quantitative
data. Statistical signiﬁcance was determined using ANOVA with the
Tukey's multiple comparison test, unpaired or paired t-tests. P-va-
lues < .05 were considered statistically signiﬁcant.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jconrel.2019.07.006.
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